Cancer52 is proud to launch their report ‘Improving diagnosis: Patient and clinician perspectives on increasing early diagnosis in rare and less common cancers’
Read report: https://bit.ly/earlcandiag
Cancer52 worked with its members, biotech company GRAIL, and consultancy Incisive Health to take a deep dive led by patients, carers and clinicians to gain insights around what matters most in early diagnosis.
The resulting report offers a constructive contribution on how to measure early diagnosis, including for non-stageable cancers such as blood and brain, that have previously been outside of NHS targets. These policy recommendations for the next National Cancer Plan for England include suggestions for measuring early diagnosis at an early and actionable point where interventions will be most effective, and achieve the biggest improvements to outcomes and quality of life.
Huge thanks to the Cancer52 members who supported this work by suggesting patients and clinician to interview, as well as contributing expertise in several online meetings.
Comments